338 related articles for article (PubMed ID: 27350261)
1. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.
Kanaji N; Tadokoro A; Kita N; Murota M; Ishii T; Takagi T; Watanabe N; Tojo Y; Harada S; Hasui Y; Kadowaki N; Bandoh S
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1855-65. PubMed ID: 27350261
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy.
Kanaji N; Shimizu J; Sakai K; Ueda Y; Miyawaki H; Watanabe N; Uemura T; Hida T; Inoue T; Watanabe N; Oohara Y; Dobashi H; Kato M; Kadowaki N
Ther Adv Respir Dis; 2020; 14():1753466620963866. PubMed ID: 33086985
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis.
Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Nishiyama O; Kondo M; Hasegawa Y
Respiration; 2013; 85(4):326-31. PubMed ID: 23171837
[TBL] [Abstract][Full Text] [Related]
4. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis.
Saito Y; Kawai Y; Takahashi N; Ikeya T; Murai K; Kawabata Y; Hoshi E
Ann Thorac Surg; 2011 Nov; 92(5):1812-7. PubMed ID: 21944440
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
Koyama N; Iwai Y; Nagai Y; Aoshiba K; Nakamura H
PLoS One; 2019; 14(8):e0221718. PubMed ID: 31442290
[TBL] [Abstract][Full Text] [Related]
7. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
9. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
10. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
11. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
[TBL] [Abstract][Full Text] [Related]
12. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
[TBL] [Abstract][Full Text] [Related]
13. Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation.
Moon SW; Park MS; Kim YS; Jang J; Lee JH; Lee CT; Chung JH; Shim HS; Lee KW; Kim SS; Lee SH; Yoon HI
BMC Pulm Med; 2019 Oct; 19(1):177. PubMed ID: 31615505
[TBL] [Abstract][Full Text] [Related]
14. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
16. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
17. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors.
Voltolini L; Bongiolatti S; Luzzi L; Bargagli E; Fossi A; Ghiribelli C; Rottoli P; Gotti G
Eur J Cardiothorac Surg; 2013 Jan; 43(1):e17-23. PubMed ID: 23129356
[TBL] [Abstract][Full Text] [Related]
18. Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Mar; 12(5):667-675. PubMed ID: 33480111
[TBL] [Abstract][Full Text] [Related]
19. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis.
Khan KA; Kennedy MP; Moore E; Crush L; Prendeville S; Maher MM; Burke L; Henry MT
Lung; 2015 Feb; 193(1):71-7. PubMed ID: 25381634
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic pulmonary fibrosis in patients with early-stage non-small-cell lung cancer after surgical resection.
Nezka H; Igor P; Izidor K
Radiol Oncol; 2019 Sep; 53(3):357-361. PubMed ID: 31553706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
